Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:49 PM
Ignite Modification Date:
2025-12-24 @ 9:49 PM
NCT ID:
NCT04361032
Eligibility Criteria:
Inclusion Criteria:
* Patient confirmed COVID19 positive
* Patient with acute respiratory deficiency
* Patient hospitalized in the intensive care unit
* Age \>18 years old
* Having given written consent for their participation in the study
Exclusion Criteria:
* Taking Tocilizumab or hydroxychloroquine deferoxamine within one month prior to inclusion (excluding participation in THINC or COVID\_2Pro or COVID+PA studies)
* Severe/severe liver failure
* Dialysis patients
* Renal insufficiency (clearance\< 30ml/min/1.73m2)
* Allergy to deferoxamine
* Pregnant or breastfeeding woman
* Hypersensitivity to the active substance or any of the excipients of Tocilizumab
* A decrease in blood platelets with previous use of enoxaparin or another heparin drug,
* hemophilia and related diseases,
* stomach or duodenal ulcer
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT04361032
Study Brief:
Protocol Section:
NCT04361032